Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26790797 | 0.87 | DPP4 (0.33) | DPP4 | |
| SCHEMBL26790873 | 0.83 | DPP4 (0.34) | DPP4DPP8 | |
| SCHEMBL26790803 | 0.82 | DPP4 (0.38) | DPP4DPP8 | |
| SCHEMBL26790843 | 0.77 | — | — | |
| SCHEMBL24463239 | 0.74 | DPP4 (0.37) | DPP4DPP8 | |
| SCHEMBL30390911 | 0.74 | DPP4 (0.37) | DPP4DPP8 | |
| SCHEMBL26790544 | 0.72 | GRM5 (0.39) | — | |
| SCHEMBL26790691 | 0.72 | GRM5 (0.39) | DPP4 | |
| SCHEMBL26790794 | 0.71 | DPP4 (0.35) | DPP4 | |
| SCHEMBL26790835 | 0.69 | ADORA2A (0.31) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | DPP4 2192/4885DPP8 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.